SCHEMBL3614432

SCHEMBL3614432

O=[N+]([O-])c1ccc(-c2cccnc2)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 12/20 1.00
CYP2C19 P33261 8/20 0.53
CYP2C9 P11712 7/20 0.53
CYP3A4 P08684 6/20 0.53
CYP2D6 P10635 6/20 0.53
CYP2E1 P05181 5/20 0.53
CYP2B6 P20813 5/20 0.53
MKNK1 Q9BUB5 1/20 0.51
MKNK2 Q9HBH9 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598546 0.85 CYP2A6 (0.72) CYP2A6CYP2C19CYP3A4L3MBTL1ALDH1A1
SCHEMBL22834157 0.81 CYP2A6 (0.68) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL6067937 0.80 CYP2A6 (0.67) CYP2A6CYP2C19CYP2C9CYP3A4CYP2E1
SCHEMBL29854440 0.78 CYP2A6 (0.73) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL1255021 0.75 CYP2A6 (0.59) CYP2A6MKNK1MKNK2ALOX5ALDH1A1
SCHEMBL9777499 0.73 CYP2A6 (0.56) CYP2A6L3MBTL1ALOX5ALDH1A1MITF
SCHEMBL9200850 0.72 CYP2A6 (0.66) CYP2A6CYP2C19CYP2C9CYP3A4CYP2D6
SCHEMBL22834280 0.72 CYP2A6 (0.56) CYP2A6CYP2C19CYP2C9L3MBTL1ALOX5
SCHEMBL22834314 0.72 CYP2A6 (0.56) CYP2A6CYP2C19CYP2C9CYP3A4L3MBTL1
SCHEMBL14332592 0.72 CYP2A6 (0.56) CYP2A6ALOX5MITFMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220332695-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RESEARCH TRIANGLE INSTITUTE 2022-10-20 US disclosed
EP-3990112-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RTI International (US) 2022-05-04 EP disclosed
WO-2020264176-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RTI INTERNATIONAL (US) 2020-12-30 WO disclosed
US-8609708-B2 Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2013-12-17 US disclosed
CN-102470127-A Biaryl compounds and methods of use thereof AMBIT BIOSCIENCES CORP 2012-05-23 CN disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
WO-2005066162-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer CYP2A13, CYP2A6, CYP2B6 CYP2A6 2/4885CYP2C19 41/4885CYP2C9 44/4885
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER CYP2A13, CYP2A6, CYP2B6 CYP2A6 2/4885CYP2C19 41/4885CYP2C9 44/4885
US-20220332695-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS CNR1, CNR2, GPR119 CYP2A6 332/4885CYP2C19 564/4885CYP2C9 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.